Detalhe da pesquisa
1.
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
Breast Cancer Res;
18(1): 70, 2016 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27368372
2.
A human fatty acid synthase inhibitor binds ß-ketoacyl reductase in the keto-substrate site.
Nat Chem Biol;
10(9): 774-9, 2014 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25086508
3.
Subtype and pathway specific responses to anticancer compounds in breast cancer.
Proc Natl Acad Sci U S A;
109(8): 2724-9, 2012 Feb 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22003129
4.
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
Breast Cancer Res;
19(1): 17, 2017 02 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28183333
5.
Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.
Bioorg Med Chem Lett;
22(6): 2230-4, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22361133
6.
Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent ß isoform selective phosphatidylinositol 3-kinase inhibitors.
Bioorg Med Chem Lett;
22(9): 3198-202, 2012 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22475557
7.
High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916.
J Transl Med;
9: 110, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21762492
8.
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.
Bioorg Med Chem Lett;
20(8): 2552-5, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20335034
9.
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
Biochem J;
420(2): 259-65, 2009 May 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19284385
10.
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Cancer Res;
66(3): 1640-7, 2006 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16452223
11.
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors.
ACS Med Chem Lett;
7(3): 217-22, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26985301
12.
[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase ß Inhibitors.
ACS Med Chem Lett;
4(2): 230-4, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24900655
13.
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.
ACS Med Chem Lett;
3(7): 524-9, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24900504
14.
Molecular target class is predictive of in vitro response profile.
Cancer Res;
70(9): 3677-86, 2010 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20406975
15.
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
J Med Chem;
53(10): 3973-4001, 2010 May 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20420387
16.
Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics.
Cell Cycle;
8(11): 1733-7, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19395863
17.
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Mol Cancer Ther;
8(7): 1808-17, 2009 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19567821